Literature DB >> 6448114

Con A-induced suppressor cells in children with acute lymphoblastic leukaemia.

M Eibl, P Krepler, W Schmidmeier, C Zielinski, H Winterleitner.   

Abstract

The function of Con A stimulation was investigated in patients with ALL in remission and in patients with ALL in the acute phase of the disease as compared to healthy controls. Suppression of the Con A response brought about by autologous Con A-activated cells was significantly lower in ALL patients in remission (mean value 29.33%) and in the acute phase (mean value 10%) than in the controls (mean value 64.86%). Suppression of the Con A stimulation of control lymphocytes by Con A-activated homologous cells of ALL patients had a mean value of 51.65%. This was significantly higher than the suppression obtained by the same ALL cells in the autologous system and of the same order of magnitude as the suppression obtained by control Con A-activated cells on control Con A stimulation (57.67%). Suppression of the Con a response of ALL lymphocytes produced by control Con A-activated cells was 23.17% and comparable to healthy controls. These results demonstrate that the function of Con A-induced suppression is significantly lower in ALL patients. They further indicate that at least two cell types are involved in this kind of suppression in humans.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448114      PMCID: PMC1538948     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Combined modality therapy of acute lymphocytic leukemia.

Authors:  J V Simone; R J Aur; H O Hustu; M Verzosa; D Pinkel
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

2.  Dissociation of lymphotoxin production and lymphocyte blast cell transformation in acute lymphoblastic leukemia after cessation of long-term immunosuppressive therapy.

Authors:  R Eife; L Trowitzsch; F Lampert
Journal:  Klin Padiatr       Date:  1974-11       Impact factor: 1.349

3.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

Review 4.  Suppressor T cells in cell-mediated immunity.

Authors:  G L Asherson; M Zembala
Journal:  Br Med Bull       Date:  1976-05       Impact factor: 4.291

5.  The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.

Authors:  T A Waldmann; S Broder; R Krakauer; R P MacDermott; M Durm; C Goldman; B Meade
Journal:  Fed Proc       Date:  1976-07

6.  Subpopulations of human T cells identified by receptors for immunoglobulins and mitogen responsiveness.

Authors:  L Moretta; M Ferrarini; M C Mingari; A Moretta; S R Webb
Journal:  J Immunol       Date:  1976-12       Impact factor: 5.422

7.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

8.  Cell-mediated immune responsiveness of patients with acute lymphocytic leukemia in remission.

Authors:  R K Oldham; R S Weiner; G Mathé; J Breard; M C Simmler; P Carde; R B Herberman
Journal:  Int J Cancer       Date:  1976-03-15       Impact factor: 7.396

9.  The role of irradiation in central nervous system treatment and prophylaxis for acute lymphoblastic leukemia.

Authors:  A Dritschilo; J R Cassady; B Camitta; N Jaffe; L Furman; D Traggis
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  1 in total

1.  Enhanced clonability of human T lymphocytes caused by their culturing in vitro.

Authors:  A Górski; Z Gaciong; B Dupont
Journal:  Immunology       Date:  1981-11       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.